Literature DB >> 19616498

Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

F M Russell1, A Balloch, M L K Tang, J R Carapetis, P Licciardi, J Nelson, A W J Jenney, L Tikoduadua, L Waqatakirewa, J Pryor, G B Byrnes, Y B Cheung, E K Mulholland.   

Abstract

The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor countries. Fijian infants received zero, one, two, or three doses of 7-valent pneumococcal conjugate vaccine (PCV) in early infancy. Following three PCV doses, geometric mean concentration (GMC) to all seven serotypes were > or = 1.0 microg/mL, and >85% of children achieved antibody levels > or = 0.35 microg/mL at 18 weeks. Following two doses, GMC were lower for 6B, 14, and 23F, but higher for 19F compared with three doses. Following a single dose, significant responses were seen for all serotypes post-primary series compared with the unvaccinated. By 12 months, differences between two and three doses persisted for serotype 14 only. Although GMC following three doses are higher than after two doses, the differences were small. A single dose may offer some protection for most serotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616498      PMCID: PMC2734870          DOI: 10.1016/j.vaccine.2009.06.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.

Authors:  J Eskola; J Ward; R Dagan; D Goldblatt; F Zepp; C A Siegrist
Journal:  Lancet       Date:  1999-12-11       Impact factor: 79.321

Review 2.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

5.  Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.

Authors:  Taneli Puumalainen; Ron Dagan; Tomi Wuorimaa; Rose Zeta-Capeding; Marilla Lucero; Jukka Ollgren; Helena Käyhty; Hanna Nohynek
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

6.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

7.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.

Authors:  Robin E Huebner; Nontombi Mbelle; Bruce Forrest; Dace V Madore; Keith P Klugman
Journal:  Pediatr Infect Dis J       Date:  2002-11       Impact factor: 2.129

10.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  25 in total

1.  Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.

Authors:  F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

2.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

3.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

4.  Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Moon H Nahm; Kim Mulholland; Mimi L K Tang
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

5.  Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used.

Authors:  Anne Balloch; Paul V Licciardi; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

6.  Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Authors:  Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

7.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

8.  Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

Authors:  F M Russell; A Balloch; P V Licciardi; J R Carapetis; L Tikoduadua; L Waqatakirewa; Y B Cheung; E K Mulholland; M L K Tang
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

9.  Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction.

Authors:  Mohamed Tashani; Sanjay Jayasinghe; Zitta B Harboe; Harunor Rashid; Robert Booy
Journal:  World J Clin Pediatr       Date:  2016-08-08

10.  Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.

Authors:  Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.